Please use this identifier to cite or link to this item:
Title: Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis
Authors: Attapon Cheepsattayakorn
Ruangrong Cheepsattayakorn
Authors: Attapon Cheepsattayakorn
Ruangrong Cheepsattayakorn
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 23-Jul-2012
Abstract: A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide. © 2012 Bentham Science Publishers.
ISSN: 1574891X
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.